Renal and Hematology: Positive 52-week data from Phase 3 active-controlled studies of vadadustat, a treatment for patients with anemia due to chronic kidney disease (CKD)

http://ir.akebia.com/news-releases/news-release-details/akebia-announces-positive-52-week-efficacy-and-safety-data